GeneDx (NASDAQ:WGS – Get Free Report) was upgraded by equities research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued on Tuesday,Zacks.com reports.
Other research analysts have also recently issued research reports about the stock. Piper Sandler restated an “overweight” rating and set a $63.00 price objective (up from $50.00) on shares of GeneDx in a report on Tuesday, June 23rd. Canaccord Genuity Group set a $75.00 target price on shares of GeneDx and gave the stock a “buy” rating in a report on Tuesday, May 5th. Weiss Ratings cut shares of GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 1st. Wall Street Zen lowered shares of GeneDx from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, BTIG Research lowered their price objective on shares of GeneDx from $170.00 to $90.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $87.43.
Check Out Our Latest Stock Report on WGS
GeneDx Price Performance
GeneDx (NASDAQ:WGS – Get Free Report) last announced its quarterly earnings results on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). The company had revenue of $102.25 million during the quarter, compared to the consensus estimate of $112.46 million. GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. During the same period last year, the company earned ($0.23) earnings per share. On average, equities analysts anticipate that GeneDx will post -1 EPS for the current year.
Insider Activity at GeneDx
In other GeneDx news, Director Casdin Capital, Llc bought 185,000 shares of the stock in a transaction that occurred on Tuesday, May 19th. The stock was acquired at an average cost of $42.60 per share, with a total value of $7,881,000.00. Following the purchase, the director owned 3,367,164 shares in the company, valued at $143,441,186.40. This trade represents a 5.81% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Keith A. Meister bought 533,758 shares of the company’s stock in a transaction on Thursday, May 7th. The shares were bought at an average price of $37.86 per share, for a total transaction of $20,208,077.88. Following the completion of the acquisition, the director directly owned 3,761,908 shares in the company, valued at approximately $142,425,836.88. This trade represents a 16.53% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders purchased 2,256,420 shares of company stock valued at $93,144,340 and sold 19,135 shares valued at $1,128,499. 25.17% of the stock is currently owned by insiders.
Institutional Investors Weigh In On GeneDx
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada lifted its position in GeneDx by 30.2% in the 1st quarter. Royal Bank of Canada now owns 29,479 shares of the company’s stock valued at $2,611,000 after acquiring an additional 6,840 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in GeneDx by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock worth $677,000 after purchasing an additional 453 shares in the last quarter. NewEdge Advisors LLC increased its holdings in GeneDx by 270,700.0% during the 1st quarter. NewEdge Advisors LLC now owns 2,708 shares of the company’s stock worth $240,000 after purchasing an additional 2,707 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of GeneDx by 67.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company’s stock valued at $2,500,000 after purchasing an additional 11,375 shares during the period. Finally, Cetera Investment Advisers acquired a new stake in shares of GeneDx in the 2nd quarter valued at about $249,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.
Key GeneDx News
Here are the key news stories impacting GeneDx this week:
- Positive Sentiment: GeneDx has an average analyst recommendation of “Moderate Buy,” suggesting some analysts continue to see recovery or long-term value in the company despite recent volatility. GeneDx analyst recommendation
- Negative Sentiment: Multiple law firms announced or promoted a securities class action against GeneDx and certain officers. The case covers investors who purchased shares from April 16, 2025, through May 4, 2026, with an August 3, 2026 deadline to seek lead-plaintiff status. The repeated notices increase the visibility of the legal risk and may weigh on investor confidence. GeneDx class action announcement
- Negative Sentiment: The allegations focus on claims that GeneDx concealed deteriorating reimbursement rates and margin compression. Other notices allege that the company overstated the performance and strategic benefits of its Fabric Genomics acquisition, which allegedly resulted in a $31.2 million write-off and contributed to a roughly 49% stock decline. These are allegations, not proven findings. GeneDx shareholder alert
- Negative Sentiment: The litigation headlines add to existing fundamental concerns: GeneDx’s latest reported quarter missed both revenue and EPS expectations, and analysts expect a full-year loss. Potential legal costs, settlement exposure, and additional scrutiny could further pressure the valuation. GeneDx deadline alert
GeneDx Company Profile
GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.
Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.
Read More
- Five stocks we like better than GeneDx
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.
